Kings College London: A Novel Gene Therapy Addressing Recessive Dystrophic Epidermolysis Bullosa (RDEB) Shows Promise

Kings College London: A Novel Gene Therapy Addressing Recessive Dystrophic Epidermolysis Bullosa (RDEB) Shows Promise

Jul 27, 2019 | Gene-Modified Autologous Fibroblasts, Kings College London, Recessive Dystrophic Epidermolysis Bullosa, Stem Cell

King’s College London, in collaboration with University College, London conducted a Phase I clinical trials focused on recessive dystrophic epidermolysis bullosa (RDEB), a severe form of blistering skin disease caused by mutations in COL7A1 gene. The UK-based study...

Pin It on Pinterest